PARPBP and myeloid leukemia: Intriguingly, a previous study showed that in certain malignancies such as myeloid leukemia cells [5], hepatocellular cancer [6] and pancreatic cancer [7], the upregulation of C12orf48 expression has been detected, suggesting that C12orf48 could be a potential inhibiting target for novel therapeutic anticancer treatment.